![John Ingram MA MSc DM(Oxon) FRCP(Derm) FAcadMEd](https://profiles-cardiff.imgix.net/attachments/2464?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Professor John Ingram
(he/him)
MA MSc DM(Oxon) FRCP(Derm) FAcadMEd
Teams and roles for John Ingram
Clinical Professor
Overview
Improving the care of people with hidradenitis suppurativa is my principal research and clinical focus within dermatology. Hidradenitis suppurativa (HS) is a painful chronic inflammatory skin disease, characterised by recurrent skin boils in flexural sites, producing a large impact on quality of life and affecting about 1% of the population globally.
I am a co-founder of HiSTORIC, the core outcome domains global collaboration for HS and Chief Investigator of H-STRONG, the UK-Irish Treatment Registry Study. Previously I led several HS research consortia, including the Cochrane Review of Interventions for HS, James Lind Alliance HS Priority Setting Partnership, the British Association of Dermatologists HS Guideline Development Group, and the HTA-funded THESEUS study. I run a HS multidisciplinary clinic in Cardiff and champion a holistic approach to HS care, integrating medical and surgical therapy.
I am also immediate past Editor-in-Chief of the British Journal of Dermatology (https://academic.oup.com/bjd), impact factor 11.0, ranked third of the 94 dermatology journals, leading the journal from 2019-2024.
Publication
2025
- Bechara, F. G. et al., 2025. Towards a paradigm shift in delivering hidradenitis suppurativa care: a narrative review. Dermatology and Therapy 15 , pp.2317-2333. (10.1007/s13555-025-01462-7)
- Bouazzi, D. et al., 2025. Prevalence of hidradenitis suppurativa. JAMA Dermatology 161 (10), pp.1022-1028. (10.1001/jamadermatol.2025.2373)
- Garg, A. et al., 2025. Standardization of lesion classification and assessment by investigators in clinical trials for hidradenitis suppurativa. JAMA Dermatology (10.1001/jamadermatol.2025.4652)
- Gribaleva, E. et al., 2025. The UK-Irish Atopic eczema Systemic TherApy Register (A*STAR): Baseline characteristics of the cohort. British Journal of Dermatology 192 (5), pp.927-930. (10.1093/bjd/ljaf039)
- Holgersen, N. et al., 2025. Impact of psychiatric disease and treatment on biologic drug survival in patients with hidradenitis suppurativa. Journal of The American Academy of Dermatology (10.1016/j.jaad.2025.09.037)
- Howells, L. et al., 2025. A qualitative interview study exploring patient views and experiences of treatment for hidradenitis suppurativa in the UK. British Journal of Dermatology 193 (1), pp.85-92. ljaf046. (10.1093/bjd/ljaf046)
- Hundal, S. et al., 2025. Cost-utility analysis of clinic-based deroofing versus local excision for hidradenitis suppurativa. Journal of The American Academy of Dermatology 92 (4), pp.773-780. (10.1016/j.jaad.2024.11.057)
- Ingram, J. R. et al. 2025. Hidradenitis suppurativa with and without draining tunnels: A real-world study characterizing differences in treatment and disease burden. Journal of the European Academy of Dermatology and Venereology (10.1111/jdv.20550)
- Ingram, J. R. 2025. Hidradenitis suppurativa: BJD state-of-the-art review series. British Journal of Dermatology 192 (Supp_1), pp.i1-i2. (10.1093/bjd/ljae455)
- Ingram, J. R. 2025. Mechanistic insights into ruxolitinib cream for mild hidradenitis suppurativa. British Journal of Dermatology 192 (5), pp.789-790. ljaf019. (10.1093/bjd/ljaf019)
- Ingram, J. R. et al. 2025. Bimekizumab pain outcomes in patients with hidradenitis suppurativa: pooled 48-week results from BE HEARD I&II phase 3 randomized clinical trials. Pain and Therapy 14 , pp.1861-1878. (10.1007/s40122-025-00779-7)
- Ingram, J. R. et al. 2025. Implementation science to improve the diagnosis and management of hidradenitis suppurativa: HELyx study design overview. Dermatology and Therapy 15 (2), pp.463–472. (10.1007/s13555-025-01350-0)
- Ingram, J. R. et al. 2025. Hidradenitis suppurativa symptom daily diary (HSSDD) and questionnaire (HSSQ): psychometric validation and interpretation threshold derivation using phase 3 study data. Dermatology and Therapy 15 , pp.1093-1111. (10.1007/s13555-025-01346-w)
- Ingram, J. R. et al. 2025. Assessing long-term pain reduction with secukinumab in moderate to severe hidradenitis suppurativa: a post hoc analysis of the SUNSHINE and SUNRISE Phase 3 trials. Dermatology and Therapy (10.1007/s13555-025-01426-x)
- Ingram, J. R. et al. 2025. The Hidradenitis suppurativa symptom and impact diary: development and psychometric evaluation of a novel set of patient reported outcomes for hidradenitis suppurativa. British Journal of Dermatology 193 (6), pp.1155-1164. (10.1093/bjd/ljaf307)
- Kirby, J. S. et al., 2025. Psychometric validation and interpretation thresholds of the Hidradenitis Suppurativa Quality of Life (HiSQOL©) questionnaire using pooled data from the Phase 3 BE HEARD I & II trials of bimekizumab in hidradenitis suppurativa. British Journal of Dermatology 193 (1), pp.93-104. (10.1093/bjd/ljaf067)
- Li, Y. H. et al., 2025. Comparing maximum and average numerical rating scale pain scores in hidradenitis suppurativa. Archives of Dermatological Research 317 (1) 496. (10.1007/s00403-025-03943-3)
- Nikolakis, G. et al., 2025. Towards the development of upgrade criteria for the treatment of hidradenitis suppurativa with biologics. Journal of the European Academy of Dermatology and Venereology (10.1111/jdv.70118)
- Pickles, T. and Ingram, J. R. 2025. Minimal important difference of pain numeric rating scale in patients with Hidradenitis suppurativa: results from THESEUS. British Journal of Dermatology 192 (4), pp.761-763. ljae486. (10.1093/bjd/ljae486)
- Sampath, A. J. et al., 2025. Standardized protocols for clinical and histopathological characterization of hidradenitis suppurativa tissue specimens. Journal of Investigative Dermatology 145 (1), pp.50-55. (10.1016/j.jid.2024.02.041)
- Sayed, C. J. et al., 2025. Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension. Journal of The American Academy of Dermatology (10.1016/j.jaad.2025.11.031)
- Shah, R. et al. 2025. Comparison of the impact of type 1 and type 2 diabetes on quality of life of families of patients: A UK cross‐sectional study. Diabetes, Obesity and Metabolism 27 (2), pp.652-662. (10.1111/dom.16058)
- Shah, R. et al. 2025. Multiple sclerosis greatly impacts family members/partners: Evidence using the Family Reported Outcome Measure (FROM-16). Multiple Sclerosis Journal - Experimental, Translational and Clinical 11 (2) 20552173251338762. (10.1177/20552173251338762)
- Shi, V. Y. et al., 2025. Bimekizumab impact on patient-reported outcomes in patients with moderate to severe hidradenitis suppurativa: pooled 48-week results from BE HEARD I&II. Dermatology and Therapy 15 , pp.2553-2570. (10.1007/s13555-025-01465-4)
- Thorlacius, L. et al., 2025. The HIdradenitis suppurativa DrainagE (HIDE) Scale: development and content validation of patient reported outcome measure [Research Letter]. British Journal of Dermatology 193 (6), pp.1242-1244. (10.1093/bjd/ljaf317)
- van Dalen, S. C. M. et al., 2025. Neutrophil extracellular traps are widely distributed across lesional and perilesional hidradenitis suppurativa skin, and elevated serum NET markers associate with moderate to severe HS disease. International Journal of Dermatology 64 (7), pp.1234-1241. (10.1111/ijd.17706)
- Vyas, J. et al. 2025. A systematic review of the use of the Dermatology Life Quality Index (DLQI) in routine clinical practice: evidence from 287 articles across 56 countries. Clinical and Experimental Dermatology 50 (12), pp.2456-2465. (10.1093/ced/llaf343)
- Wainman, H. E. et al., 2025. Management of hidradenitis suppurativa in UK primary care: cross-sectional survey. British Journal of General Practice Open (10.3399/BJGPO.2025.0060)
- Wainman, H. E. et al., 2025. Is there still a role for clindamycin and rifampicin in the treatment of hidradenitis suppurativa: A review of the literature. Clinical and Experimental Dermatology 50 (8), pp.1671-1676. (10.1093/ced/llaf160)
- Westerkam, L. L. et al., 2025. Establishment of standardized definitions and a core set of outcome characteristics following hidradenitis suppurativa surgery developed by an expert Delphi consensus. Journal of The American Academy of Dermatology 93 (6), pp.1499-1508. (10.1016/j.jaad.2025.08.041)
- Zouboulis, C. C. et al., 2025. European S2k guidelines for hidradenitis suppurativa/acne inversa part 2: Treatment. Journal of the European Academy of Dermatology and Venereology 39 (5), pp.899-941. (10.1111/jdv.20472)
2024
- Ahmed, A. et al., 2024. Clinical relevance and uptake of core outcome sets in dermatology [Research letter]. Archives of Dermatological Research 316 (2) 78. (10.1007/s00403-023-02814-z)
- Ahmed, A. et al., 2024. Methodological innovations and stakeholder involvement in core outcome sets for skin diseases: a survey of the C3 working groups. Archives of Dermatological Research 316 (4) 109. (10.1007/s00403-023-02812-1)
- Alexander, H. et al., 2024. A prospective observational cohort study comparing the treatment effectiveness and safety of ciclosporin, dupilumab and methotrexate in adult and paediatric patients with atopic dermatitis: results from the UK-Irish A-STAR register. British Journal of Dermatology 191 (6), pp.988-999. (10.1093/bjd/ljae287)
- Bouazzi, D. et al., 2024. The Global Hidradenitis Suppurativa Atlas (GHiSA) methodology: Combining global proportions in a pooled analysis. Dermatology 240 (3), pp.369-375. (10.1159/000536389)
- Garg, A. et al., 2024. Addressing high placebo response rates in randomized clinical trials for hidradenitis suppurativa. British Journal of Dermatology 190 (3), pp.427-429. (10.1093/bjd/ljad375)
- Hasan, S. B. et al. 2024. Feasibility of daily pain measurement using text messages in Hidradenitis Suppurativa clinical trials; Data from THESEUS study. British Journal of Dermatology 190 (5), pp.775-777. ljae057. (10.1093/bjd/ljae057)
- Hernandez-Cordero, A. et al., 2024. A genome-wide meta-analysis of palmoplantar pustulosis implicates TH2 responses and cigarette smoking in disease pathogenesis. Journal of Allergy and Clinical Immunology 154 (3), pp.657-665. (10.1016/j.jaci.2024.05.015)
- Ingram, J. R. et al. 2024. Treatment of hidradenitis suppurativa evaluation study (THESEUS): a prospective cohort study. British Journal of Dermatology 190 (3), pp.382-391. (10.1093/bjd/ljad388)
- Ingram, J. R. et al. 2024. Treatment satisfaction in patients with hidradenitis suppurativa: A real-world survey from the EU5 and US. Dermatology (10.1159/000542343)
- Ingram, J. R. et al. 2024. Comprehensive codified algorithms to identify the underestimated burden of hidradenitis suppurativa in the United States. Dermatology and Therapy 14 , pp.2859–2876. (10.1007/s13555-024-01259-0)
- Johns, J. R. et al. 2024. The Dermatology Life Quality Index as the primary outcome in randomized clinical trials: a systematic review. British Journal of Dermatology 191 (4), pp.497-507. (10.1093/bjd/ljae228)
- Kimball, A. B. et al., 2024. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials. The Lancet 403 (10443), pp.2504-2519. (10.1016/S0140-6736(24)00101-6)
- Kimball, A. B. et al., 2024. Burden of hidradenitis suppurativa: a systematic literature review of patient reported outcomes. Dermatology and Therapy 14 , pp.83–98. (10.1007/s13555-023-01085-w)
- Nadir, U. et al., 2024. Protocol of a scoping review of outcome domains in dermatology. BMJ Open 14 (2) e079632. (10.1136/bmjopen-2023-079632)
- Navarrete-Dechent, C. et al., 2024. The road to publication: Advice from journal editors. Journal of The American Academy of Dermatology 90 , pp.707-710. (10.1016/j.jaad.2023.11.038)
- Oyesiku, L. et al., 2024. Inclusive and equitable language for skin colour in the British Journal of Dermatology: acknowledging our past and laying the foundations to move forward. British Journal of Dermatology 190 (5), pp.605–607. (10.1093/bjd/ljae064)
- Ring, H. C. et al., 2024. Long-term drug survival of adalimumab, infliximab, secukinumab and ustekinumab in hidradenitis suppurativa: A Danish nationwide cohort study. British Journal of Dermatology 190 (5), pp.769-771. ljae042. (10.1093/bjd/ljae042)
- Shah, R. et al. 2024. Measurement of the major ignored burden of multiple myeloma, pernicious anaemia and of other haematological conditions on partners and family members: A cross‐sectional study. European Journal of Haematology 113 (1), pp.117-126. (10.1111/ejh.14206)
- Shah, R. et al. 2024. Responsiveness and minimal important change of the Family Reported Outcome Measure (FROM-16). Journal of Patient-Reported Outcomes 8 (1) 38. (10.1186/s41687-024-00703-1)
- Shah, R. et al. 2024. Mapping of family reported outcome measure (FROM-16) scores to EQ-5D: algorithm to calculate utility values. Quality of Life Research 33 , pp.1107-1119. (10.1007/s11136-023-03590-z)
- Shah, R. et al. 2024. Dementia and its profound Impact on family members and partners. Alzheimer Disease & Associated Disorders 38 (4), pp.338-342. (10.1097/WAD.0000000000000647)
- Vyas, J. et al. 2024. The Dermatology Life Quality Index (DLQI) used as the benchmark in validation of 101 quality of life instruments: A systematic review. Journal of the European Academy of Dermatology and Venereology (10.1111/jdv.20321)
- Vyas, J. et al. 2024. A systematic review of 207 studies describing validation aspects of the dermatology life quality index. Acta Dermato-Venereologica 104 adv41120. (10.2340/actadv.v104.41120)
- Vyas, J. et al. 2024. A systematic review of 457 randomised controlled trials using the Dermatology Life Quality Index: experience in 69 diseases and 43 countries. British Journal of Dermatology 190 (3), pp.315-339. (10.1093/bjd/ljad079)
- Wainman, H. E. et al., 2024. Global consensus process to establish a core data set for hidradenitis suppurativa registries. British Journal of Dermatology 190 (4), pp.510-518. (10.1093/bjd/ljad454)
2023
- Ahmed, S. et al., 2023. Visualising complexity: embracing graphical abstracts in the BJD [Editorial]. British Journal of Dermatology 189 (2), pp.149-150. (10.1093/bjd/ljad181)
- Bosma, A. L. et al., 2023. Comparison of real-world treatment outcomes of systemic immunomodulating therapy in atopic dermatitis patients with dark and light skin types. JAAD International 10 , pp.14-24. (10.1016/j.jdin.2022.09.006)
- Garg, A. et al., 2023. Factors associated with disease-specific life impact in patients with hidradenitis suppurativa: results from the Global VOICE project. British Journal of Dermatology 188 (6), pp.808-810. (10.1093/bjd/ljad069)
- Garg, A. et al., 2023. Validation of the Hidradenitis Suppurativa Investigator Global Assessment. JAMA Dermatology 159 (6), pp.606-612. (10.1001/jamadermatol.2023.0797)
- Ingram, J. R. 2023. A watershed moment for the BJD: Authors retain their article copyright. British Journal of Dermatology 188 (1), pp.1-2. (10.1093/bjd/ljac006)
- Ingram, J. R. et al. 2023. Treatment of hidradenitis suppurativa evaluation study: the THESEUS prospective cohort study. Health Technology Assessment 27 30. (10.3310/HWNM2189)
- Ingram, J. R. et al. 2023. Electronic patient-reported outcomes in hidradenitis suppurativa: content validity and usability of the electronic hidradenitis suppurativa symptom daily diary, hidradenitis suppurativa symptom questionnaire and hidradenitis suppurativa quality of life questionnaire. Dermatology (10.1159/000534463)
- James, J. F. et al., 2023. Demographic gaps and requirements for participation: A systematic review of clinical trial designs in Hidradenitis Suppurativa. Dermatology 239 , pp.45-51. (10.1159/000526069)
- Leighton, P. et al., 2023. Research priorities in the management of Hidradenitis Suppurativa [Research Letter]. British Journal of Dermatology 189 (3), pp.343-345. (10.1093/bjd/ljad152)
- Maronese, C. A. , Ingram, J. R. and Marzano, A. V. 2023. Has the time come to assess small-molecule/biologic drug combinations for the management of moderate-to-severe hidradenitis suppurativa?. British Journal of Dermatology 189 (4), pp.467–468. (10.1093/bjd/ljad224)
- Mastacouris, N. et al., 2023. Outcome measures for the evaluation of treatment response in hidradenitis suppurativa for clinical practice. JAMA Dermatology 159 (11), pp.1258-1266. (10.1001/jamadermatol.2023.3282)
- Midgette, B. et al., 2023. Factors associated with treatment satisfaction in patients with hidradenitis suppurativa: results from the Global VOICE project. British Journal of Dermatology 187 (6), pp.927-935. (10.1111/bjd.21798)
- Shah, R. et al. 2023. Meaning of Family Reported Outcome Measure (FROM-16) severity score bands: a cross-sectional online study in the UK. BMJ Open 13 (3) e066168. (10.1136/bmjopen-2022-066168)
- Wainman, H. E. , Lane, P. C. and Ingram, J. R. 2023. Hidradenitis suppurativa diagnosis and management in primary care: not just recurrent boils. British Journal of General Practice 73 (726), pp.43-45. (10.3399/bjgp23X731733)
- Willems, D. et al., 2023. A discrete-choice experiment to elicit the treatment preferences of patients with hidradenitis suppurativa in the United States. Journal of Medical Economics (JME) 26 (1), pp.503-508. (10.1080/13696998.2023.2194804)
- Willems, D. et al., 2023. Patient preferences in the management of hidradenitis suppurativa: results of a multinational discrete choice experiment in Europe. The Patient - Patient-Centered Outcomes Research 16 (2), pp.153-164. (10.1007/s40271-022-00614-7)
- Williams, J. C. et al., 2023. Patient-reported influences on COVID-19 vaccine acceptance and hesitancy in people with hidradenitis suppurativa [Research Letter]. British Journal of Dermatology 189 (3), pp.351-353. (10.1093/bjd/ljad166)
2022
- Bates, J. et al., 2022. Treatment of Hidradenitis Suppurativa Evaluation Study (THESEUS): protocol for a prospective cohort study. BMJ Open 12 (4) e060815. (10.1136/bmjopen-2022-060815)
- Cro, S. et al., 2022. Anakinra for palmoplantar pustulosis: results from a randomized, double-blind, multicentre, two staged, adaptive placebo controlled trial (APRICOT). British Journal of Dermatology 186 (2), pp.245-256. (10.1111/bjd.20653)
- Garg, A. et al., 2022. Shifting focus from “what we do” to the “impact of what we do”: Application of outcome measures to routine clinical care in dermatology. Journal of The American Academy of Dermatology 87 , pp.83-84. (10.1016/j.jaad.2022.04.042)
- Garg, A. et al., 2022. Development and initial validation of the HS‐IGA: a novel hidradenitis suppurativa‐specific investigator global assessment for use in interventional trials. British Journal of Dermatology 187 (2), pp.203-210. (10.1111/bjd.21236)
- Hasan, S. et al. 2022. Pain measurement in painful skin conditions and rheumatoid arthritis randomized controlled trials: A scoping review to inform pain measurement in hidradenitis suppurativa. British Journal of Dermatology 187 (6), pp.846-854. (10.1111/bjd.21821)
- Howes, R. et al., 2022. The surgical management of hidradenitis suppurativa in the United Kingdom: a national survey of care pathways informing the THESEUS study. Journal of Plastic, Reconstructive and Aesthetic Surgery 75 (1), pp.240-247. (10.1016/j.bjps.2021.08.038)
- Ingram, J. et al. 2022. Unmet clinical needs and burden of disease in hidradenitis suppurativa: real-world experience from EU5 and US. Journal of the European Academy of Dermatology and Venereology 36 (9), pp.1597-1605. (10.1111/jdv.18163)
- Maghfour, J. et al., 2022. From the Cochrane Library: interventions for hidradenitis suppurativa. JMIR Dermatology 5 (1) e29966. (10.2196/29966)
- McCluskey, D. et al., 2022. Single-cell analysis implicates Th17-to-Th2 cell plasticity in the pathogenesis of palmoplantar pustulosis. Journal of Allergy and Clinical Immunology 150 (4), pp.882-893. (10.1016/j.jaci.2022.04.027)
- Naik, H. B. et al., 2022. Biologic therapy is not associated with increased COVID-19 severity in Hidradenitis Suppurativa: Initial findings from the Global Hidradenitis Suppurativa COVID-19 Registry. Journal of The American Academy of Dermatology 86 (1), pp.249-252. (10.1016/j.jaad.2021.09.016)
- Ring, H. C. et al., 2022. The road to biologics in patients with hidradenitis suppurativa - a nationwide drug utilization study. British Journal of Dermatology 187 (4), pp.523-530. (10.1111/bjd.21673)
- Tatovic, D. et al. 2022. Safety of the use of gold nanoparticles conjugated with proinsulin peptide and administered by hollow microneedles as an immunotherapy in Type 1 diabetes. Immunotherapy Advances 2 (1) ltac002. (10.1093/immadv/ltac002)
- van Huizen, A. M. et al., 2022. International eDelphi study to reach consensus on the methotrexate dosing regimen in patients with psoriasis. JAMA Dermatology 158 (5), pp.561-572. (10.1001/jamadermatol.2022.0434)
- van Straalen, K. R. et al., 2022. New treatments and new assessment instruments for hidradenitis suppurativa. Experimental Dermatology 31 (s1), pp.33-39. (10.1111/exd.14609)
- Williams, J. C. et al., 2022. Biologic therapy is not associated with increased covid-19 severity in patients with hidradenitis suppurativa: updated findings from the global hidradenitis suppurativa covid-19 registry. Dermatology (10.1159/000527401)
- Yiu, Z. Z. N. et al., 2022. Checking for update…living systematic reviews and clinical practice guidelines in the BJD. British Journal of Dermatology 186 (5), pp.761-762. (10.1111/bjd.20896)
2021
- Burgin, S. et al., 2021. The essential role of dermatology publications in enhancing professional diversity, equity and inclusion. British Journal of Dermatology 185 (3), pp.473-474. (10.1111/bjd.20473)
- Burgin, S. et al., 2021. The essential role of dermatology publications in enhancing professional diversity, equity, and inclusion. Journal of Cosmetic Dermatology 20 (10), pp.3060-3061. (10.1111/jocd.14435)
- Collier, F. et al., 2021. Primary care management of hidradenitis suppurativa: a cross-sectional survey of UK GPs. British Journal of General Practice Open 0051. (10.3399/BJGPO.2021.0051)
- Drucker, A. M. and Ingram, J. R. 2021. Widening the tightrope: new abstract guidelines for BJD authors. British Journal of Dermatology 185 (4), pp.687-688. (10.1111/bjd.20498)
- Frew, J. W. et al., 2021. Global harmonization of morphological definitions in hidradenitis suppurativa for a proposed glossary. JAMA Dermatology 157 (4), pp.449-455. (10.1001/jamadermatol.2020.5467)
- Guckian, J. et al., 2021. Dermatology is finally talking about race. British Journal of Dermatology 185 (5), pp.875-876. (10.1111/bjd.20599)
- Hasan, S. B. et al. 2021. British Association of Dermatologists (BAD) national clinical audit on the management of Hidradenitis Suppurativa (HS) in the UK. Clinical and Experimental Dermatology 46 (6), pp.1023-1027. (10.1111/ced.14598)
- Howells, L. et al., 2021. Thematic synthesis of the experiences of people with Hidradenitis Suppurativa: a systematic review. British Journal of Dermatology 185 (5), pp.921-934. (10.1111/bjd.20523)
- Ingram, J. and Ahluwalia, A. 2021. The pharmacology of itch. British Journal of Dermatology 184 (1), pp.e1-e2. (10.1111/bjd.18525)
- Jedrzejczak, M. J. et al., 2021. Expert knowledge, attitudes, and practices in management of hidradenitis suppurativa pain. JAMA Dermatology 157 (4), pp.464-466. (10.1001/jamadermatol.2020.5857)
- Kirby, J. .. et al., 2021. Validation of patient global item for quality of life impact on Hidradenitis suppurativa. British Journal of Dermatology 184 (4), pp.681-687. (10.1111/bjd.19344)
- Sach, T. et al., 2021. An economic evaluation of the randomised controlled trial of topical corticosteroid and home‐based narrowband UVB for active and limited vitiligo (The HI‐Light Trial). British Journal of Dermatology 184 (5), pp.840-848. (10.1111/bjd.19554)
- Shah, R. et al. 2021. Measuring the impact of COVID-19 on the quality of life of the survivors, partners and family members: a cross-sectional international online survey. BMJ Open 11 (5) e047680. (10.1136/bmjopen-2020-047680)
- Thomas, K. et al., 2021. Randomised controlled trial of topical corticosteroid and home-based narrowband UVB for active and limited vitiligo - results of the HI-Light Vitiligo trial. British Journal of Dermatology 184 (5), pp.828-839. (10.1111/bjd.19592)
- Veysey, E. C. et al., 2021. Core outcome set implementation supported by the BJD. British Journal of Dermatology 184 (6), pp.987-989. (10.1111/bjd.20050)
- Wall, D. et al., 2021. Learning from disease registries during a pandemic: Moving toward an international federation of patient registries. Clinics in Dermatology 39 (3), pp.467-478. (10.1016/j.clindermatol.2021.01.018)
2020
- Ahmed, S. et al., 2020. Consent for publication: why it matters now more than ever. British Journal of Dermatology 183 (3), pp.409-410. (10.1111/bjd.19320)
- Altayeb, A. et al., 2020. Two cases of skin manifestations prior to the onset of COVID-19 respiratory symptoms. International Journal of Dermatology 59 (12), pp.1541-1542. (10.1111/ijd.15247)
- Freeman, E. E. et al., 2020. International collaboration and rapid harmonization across dermatologic COVID-19 registries. Journal of The American Academy of Dermatology (10.1016/j.jaad.2020.06.050)
- Garg, A. et al., 2020. Evaluating patients' unmet needs in hidradenitis suppurativa: results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project. Journal of The American Academy of Dermatology 82 (2)(10.1016/j.jaad.2019.06.1301)
- Hasan, S. , Ali, F. and Ingram, J. 2020. Cholinergic pruritus responding to Omalizumab. Clinical and Experimental Dermatology 45 (2), pp.264-266. (10.1111/ced.14052)
- Hasan, S. and Ingram, J. 2020. What has changed in the UK management of hidradenitis suppurativa from 2014 to 2019?. British Journal of Dermatology 183 (5), pp.973-975. (10.1111/bjd.19302)
- Ingram, J. R. et al. 2020. The prevalence of hidradenitis suppurativa is shown by the Secure Anonymised Information Linkage (SAIL) Databank to be one per cent of the population of Wales. British Journal of Dermatology 183 (5), pp.950-952. (10.1111/bjd.19210)
- Ingram, J. R. 2020. The epidemiology of hidradenitis suppurativa. British Journal of Dermatology 183 (6), pp.990-998. (10.1111/bjd.19435)
- Jung, F. et al., 2020. Systematic review of efficacies and adverse effects of treatments for Pityriasis lichenoides. British Journal of Dermatology 183 (6), pp.1026-1032. (10.1111/bjd.18977)
- Kirby, J. et al., 2020. The Hidradenitis Suppurativa Quality of Life (HiSQOL) score: development and validation of a measure for clinical trials. British Journal of Dermatology 183 (2), pp.340-348. (10.1111/bjd.18692)
- Millington, A. et al., 2020. Home-based narrowband UVB, topical corticosteroid or combination for children and adults with vitiligo: HI-Light Vitiligo three-arm RCT. Health Technology Assessment 24 (64), pp.1-183. (10.3310/hta24640)
- Naik, H. B. et al., 2020. Global hidradenitis suppurativa COVID-19 registry: a registry to inform data-driven management practices. British Journal of Dermatology 183 (4), pp.780-781. (10.1111/bjd.19345)
- Soriano, L. F. et al., 2020. Effectiveness of a stop smoking service in reducing cigarette smoking in patients referred from an NHS dermatology centre. British Journal of Dermatology 183 (6), pp.1119-1121. (10.1111/bjd.19378)
- Vergnano, M. et al., 2020. Loss-of-function myeloperoxidase mutations are associated with increased neutrophil counts and pustular skin disease. American Journal of Human Genetics 107 (3), pp.539-543. (10.1016/j.ajhg.2020.06.020)
- Zouboulis, C. C. et al., 2020. What causes hidradenitis suppurativa ? - 15 years after. Experimental Dermatology 29 (12), pp.1154-1170. (10.1111/exd.14214)
- Zouboulis, C. C. et al., 2020. Endpoints of clinical trials for Hidradenitis Suppurativa: proceedings of a round-table session. Experimental Dermatology 29 (S1), pp.67-72. (10.1111/exd.14123)
- Zuuren, E. J. et al., 2020. Publication of national dermatology guidelines as a research letter in the BJD : can less ever be enough?. British Journal of Dermatology 182 (6), pp.1319-1320. (10.1111/bjd.18952)
2019
- Frew, J. et al., 2019. Defining lesional, perilesional and unaffected skin in hidradenitis suppurativa: proposed recommendations for clinical trials and translational research studies. British Journal of Dermatology 181 (6)(10.1111/bjd.18309)
- Ho, B. et al., 2019. A survey of the treatment and management of patients with severe chronic spontaneous urticaria. Clinical and Experimental Dermatology 44 (3), pp.353-355. (10.1111/ced.13778)
- Ingram, J. 2019. BJD: onwards and upwards. British Journal of Dermatology 181 (1), pp.1-2. (10.1111/bjd.18034)
- Ingram, J. et al. 2019. British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018. British Journal of Dermatology 180 (5), pp.1009-1017. (10.1111/bjd.17537)
- Prinsen, C. A. et al., 2019. Navigating the landscape of core outcome set development in dermatology. Journal of the American Academy of Dermatology 81 (1), pp.297-305. (10.1016/j.jaad.2019.03.009)
- Scrivens, L. , Jacquet, L. and Ingram, J. 2019. BJD Medical Student Editors: reaching out to undergraduates in a rapidly evolving world of digital dermatology publishing. British Journal of Dermatology 180 (2), pp.251-252. (10.1111/bjd.17397)
- Wernham, A. et al., 2019. A five-year review of quality of reporting of research using clinician surveys in high-ranked dermatology journals. British Journal of Dermatology 181 (4), pp.845-847. (10.1111/bjd.17942)
2018
- Callander, J. et al. 2018. Treatment of clinically amyopathic dermatomyositis in adults: a systematic review. British Journal of Dermatology 179 (6), pp.1248-1255. (10.1111/bjd.14726)
- Garcia-Doval, I. et al., 2018. Optimizing case reports and case series: guidance on how to improve quality. British Journal of Dermatology 178 (6), pp.1257-1262. (10.1111/bjd.16467)
- George, S. and Ingram, J. 2018. BJD support for dermatology journal clubs: nurturing Sir William Osler's legacy. British Journal of Dermatology 178 (2), pp.313-314. (10.1111/bjd.16164)
- Ingram, J. et al. 2018. Levels of wound calprotectin and other inflammatory biomarkers aid in deciding which patients with a diabetic foot ulcer need antibiotic therapy (INDUCE study). Diabetic Medicine 35 (2), pp.255-261. (10.1111/dme.13431)
- Ingram, J. R. 2018. Atopic eczema and cardiovascular disease. BMJ 361 k2064. (10.1136/bmj.k2064)
- Ingram, J. R. et al. 2018. Population-based Clinical Practice Research Datalink study using algorithm modelling to identify the true burden of hidradenitis suppurativa. British Journal of Dermatology 178 (4), pp.917-924. (10.1111/bjd.16101)
- Thorlacius, L. et al., 2018. Towards global consensus on core outcomes for hidradenitis suppurativa research: an update from the HISTORIC consensus meetings I and II. British Journal of Dermatology 178 (3), pp.715-721. (10.1111/bjd.16093)
- Thorlacius, L. et al., 2018. A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process. British Journal of Dermatology 179 (3), pp.642-650. (10.1111/bjd.16672)
- Wernham, A. , Ingram, J. R. and Matin, R. 2018. Clinician surveys: time to make better use of this valuable resource for dermatologists. British Journal of Dermatology 178 (6), pp.1466-1467. (10.1111/bjd.16444)
2017
- Atwan, A. et al., 2017. Dermatology life quality index (DLQI) as a psoriasis referral triage tool. British Journal of Dermatology 177 (4), pp.e136-e137. (10.1111/bjd.15446)
- Callander, J. et al., 2017. How to write a Critically Appraised Topic: evidence to underpin routine clinical practice. British Journal of Dermatology 177 (4), pp.1007-1013. (10.1111/bjd.15873)
- Garcia-Doval, I. et al., 2017. Systematic reviews: let's keep them trustworthy. British Journal of Dermatology 177 (4), pp.888-889. (10.1111/bjd.15826)
- Ingram, J. R. 2017. Interventions for hidradenitis suppurativa. JAMA Dermatology 153 (5), pp.458-459. (10.1001/jamadermatol.2017.0432)
- Ingram, J. R. and Anstey, A. 2017. The evolution of clinical guidelines for dermatologists: GRADE, AGREE and occasionally consensus by experts. British Journal of Dermatology 176 (1), pp.3-4. (10.1111/bjd.15178)
- Ingram, J. R. and Burton, T. 2017. NICE approval of adalimumab for moderate-to-severe hidradenitis suppurativa: the end of the beginning for hidradenitis suppurativa therapeutics?. British Journal of Dermatology 176 (2), pp.281-282. (10.1111/bjd.15255)
- Mukkanna, K. S. , Stone, N. M. and Ingram, J. R. 2017. Para-phenylenediamine allergy: current perspectives on diagnosis and management. Journal of Asthma and Allergy 10 , pp.9-15. (10.2147/JAA.S90265)
- Sbidian, E. et al., 2017. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database of Systematic Reviews (12) CD011535. (10.1002/14651858.CD011535.pub2)
- Tang, H. K. C. et al., 2017. Delayed and localized pemphigus vulgaris after breast cancer radiotherapy. The Breast Journal 23 (6), pp.747-749. (10.1111/tbj.12910)
- Tappenden, P. et al., 2017. Adalimumab for treating moderate-to-severe hidradenitis suppurativa: an evidence review group perspective of a NICE single technology appraisal. PharmacoEconomics 35 (8), pp.805-815. (10.1007/s40273-017-0488-2)
- Thorlacius, L. et al., 2017. Protocol for the development of a core domain set for hidradenitis suppurativa trial outcomes. BMJ Open 7 (2) e014733. (10.1136/bmjopen-2016-014733)
- Williams, H. C. et al., 2017. Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial. Lancet 389 (10079), pp.1630-1638. (10.1016/S0140-6736(17)30560-3)
- Zouboulis, C. C. et al., 2017. Development and validation of IHS4, a novel dynamic scoring system to assess hidradenitis suppurativa/acne inversa severity. British Journal of Dermatology 177 (5), pp.1401-1409. (10.1111/bjd.15748)
2016
- Atwan, A. et al., 2016. Oral fumaric acid esters for psoriasis: abridged Cochrane systematic review including GRADE assessments. British Journal of Dermatology 175 (5), pp.873-881. (10.1111/bjd.14676)
- Daxhelet, M. et al., 2016. Establishment of a European Registry for hidradenitis suppurativa/acne inversa by using an open source software. Journal of the European Academy of Dermatology and Venereology 30 (8), pp.1424-1426. (10.1111/jdv.13267)
- Ingram, J. R. 2016. Hidradenitis suppurativa: an update. Clinical Medicine 16 (1), pp.70-73. (10.7861/clinmedicine.16-1-70)
- Ingram, J. R. 2016. The genetics of Hidradenitis Suppurativa. Dermatologic Clinics 34 (1), pp.23-28. (10.1016/j.det.2015.07.002)
- Ingram, J. R. , Hadjieconomou, S. and Piguet, V. 2016. Development of core outcome sets in hidradenitis suppurativa:a systematic review of outcome measure instruments to inform the process. British Journal of Dermatology 175 (2), pp.263-272. (10.1111/bjd.14475)
- Ingram, J. R. et al. 2016. Interventions for hidradenitis suppurativa: a Cochrane systematic review incorporating GRADE assessment of evidence quality. British Journal of Dermatology 174 (5), pp.970-978. (10.1111/bjd.14418)
- Thomas, K. S. et al., 2016. Clinical outcomes and response of patients applying topical therapy for pyoderma gangrenosum: a prospective cohort study. Journal of the American Academy of Dermatology 75 (5), pp.940-949. (10.1016/j.jaad.2016.06.016)
2015
- Atwan, A. et al., 2015. Oral fumaric acid esters for psoriasis. Cochrane Database of Systematic Reviews (8) CD010497. (10.1002/14651858.CD010497.pub2)
- Chalmers, J. R. et al., 2015. A randomized controlled trial to compare the safety and effectiveness of doxycycline (200 mg daily) with oral prednisolone (0·5 mg kg-1 daily) for initial treatment of bullous pemphigoid: a protocol for the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) trial. British Journal of Dermatology 173 (1), pp.227-234. (10.1111/bjd.13729)
- George, S. and Ingram, J. R. 2015. Introducing cover image as a new category of publication in the BJD. British Journal of Dermatology 173 (2), pp.315-315. (10.1111/bjd.13964)
- Ingram, J. R. and McPhee, M. 2015. Management of hidradenitis suppurativa: a UK survey of current practice. British Journal of Dermatology 173 (4), pp.1070-1072. (10.1111/bjd.13866)
- Ingram, J. R. and Paul, C. 2015. Academic mentorship in dermatology. British Journal of Dermatology 173 (5), pp.1113-1114. (10.1111/bjd.14197)
- Ingram, J. R. et al. 2015. Interventions for hidradenitis suppurativa. Cochrane Database of Systematic Reviews (10) CD010081. (10.1002/14651858.CD010081.pub2)
- Nankervis, H. et al., 2015. Validation of the global resource of eczema trials (GREAT database). BMC Dermatology 15 (4)(10.1186/s12895-015-0024-z)
- Ormerod, A. D. et al., 2015. Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial. BMJ 350 h2958. (10.1136/bmj.h2958)
2014
- Chin, M. F. et al., 2014. Patient-reported outcome measure of pain experienced during administration of local anaesthesia in cutaneous surgery: a tool for appraisal [Abstract]. British Journal of Dermatology 171 , pp.80-80.
- Ingram, J. 2014. Hidradenitis suppurativa outcome measures and treatment goals. British Journal of Dermatology 171 (6), pp.1293-1294. (10.1111/bjd.13396)
- Ingram, J. 2014. The quest for excellence (part 1): becoming a reviewer for the British Journal of Dermatology. British Journal of Dermatology 171 (5), pp.921-922. (10.1111/bjd.13404)
- Ingram, J. 2014. The quest for excellence (part 2): reviewing a clinical trial for the British Journal of Dermatology. British Journal of Dermatology 171 (6), pp.1277-1278. (10.1111/bjd.13445)
- Ingram, J. R. et al. 2014. The Hidradenitis Suppurativa Priority Setting Partnership. British Journal of Dermatology 171 (6), pp.1422-1427. (10.1111/bjd.13163)
- Ingram, J. R. et al. 2014. A Cochrane Systematic Review of interventions for Hidradenitis Suppurativa. Journal of Investigative Dermatology 134 , pp.S40-S40.
- Ingram, J. R. , Hughes, T. M. and Stone, N. M. 2014. Potential danger of hair dyes marketed as free from para-phenylenediamine. International Journal of Dermatology 53 (4), pp.e257-e258. (10.1111/ijd.12296)
- Warburton, K. L. et al., 2014. Management of morphoea: results of a national survey of UK clinicians. British Journal of Dermatology 171 (5), pp.1243-1245. (10.1111/bjd.13062)
2013
- Burr, M. L. et al. 2013. The natural history of eczema from birth to adult life: a cohort study. British Journal of Dermatology 168 (6), pp.1339-1342. (10.1111/bjd.12216)
- Ingram, J. R. 2013. Interpreting outcome measures and defining treatment success. British Journal of Dermatology 169 (6), pp.1177-1178. (10.1111/bjd.12709)
- Ingram, J. R. , Anderson, E. J. and Pugsley, L. 2013. Difficulty giving feedback on underperformance undermines the educational value of multi-source feedback. Medical Teacher 35 (10), pp.838-846. (10.3109/0142159X.2013.804910)
- Ingram, J. R. et al. 2013. Segmental cherry angiomas associated with extragenital lichen sclerosus: a report of two cases. Clinical and Experimental Dermatology 38 (4), pp.386-389. (10.1111/j.1365-2230.2012.04479.x)
- Ingram, J. R. and Piguet, V. 2013. Phenotypic heterogeneity in Hidradenitis Suppurativa (Acne Inversa): classification is an essential step toward personalized therapy. Journal of Investigative Dermatology 133 (6), pp.1453-1456. (10.1038/jid.2012.476)
- Ingram, J. R. et al. 2013. Absence of pathogenic γ-secretase mutations in a South Wales cohort of familial and sporadic hidradenitis suppurativa (acne inversa). British Journal Of Dermatology 168 (4), pp.874-876. (10.1111/bjd.12048)
- Matin, R. N. et al., 2013. The UK Dermatology Clinical Trials Network Trainee Group: developing evidence-based practice and research engagement among dermatology trainees. British Journal of Dermatology 169 , pp.35-35.
- Ponnambath, N. et al., 2013. Practical experience of biological treatment of very severe psoriasis: a retrospective case-cohort study of patients with a baseline Psoriasis Area and Severity Index score greater than 20 [Abstract]. British Journal of Dermatology 169 (s1), pp.41-41. (10.1111/bjd.12306)
2012
- Craig, F. F. et al., 2012. UK Dermatology Clinical Trials Network's STOP GAP trial (a multicentre trial of prednisolone versus ciclosporin for pyoderma gangrenosum): protocol for a randomised controlled trial. Trials 13 (1), pp.51. (10.1186/1745-6215-13-51)
- Enk, A. , Ingram, J. R. and Piguet, V. 2012. Future leaders: mentor investment in young investigators. Journal of Investigative Dermatology 132 (8), pp.1943-1944. (10.1038/jid.2012.55)
- Hodges, N. , Anstey, A. and Ingram, J. R. 2012. Fumaric acid esters for psoriasis: patient perceptions of an unlicensed medication [Abstract]. Journal of the American Academy of Dermatology 66 (4), pp.AB193-AB193. (10.1016/j.jaad.2011.11.809)
- Ingram, J. R. , Anstey, A. V. and Piguet, V. 2012. Combination treatment with a tumour necrosis factor antagonist and an oral retinoid: efficacy in severe acral psoriasis? [Letter]. British Journal Of Dermatology 167 (4), pp.949-951. (10.1111/j.1365-2133.2012.10983.x)
- Ingram, J. R. et al. 2012. A bum deal from wooden toilet seats: reemergence of allergic contact dermatitis. Dermatitis 23 (5), pp.244-245.
2011
- Ali, F. et al. 2011. X-linked dominant protoporphyria due to a novel mutation in ALAS2: a case report [Abstract]. British Journal of Dermatology 164 (5), pp.1167-1167. (10.1111/j.1365-2133.2011.10357.x)
- Ingram, J. R. 2011. The aetiology of acne inversa: an evolving story. British Journal of Dermatology 165 (2), pp.231-232. (10.1111/j.1365-2133.2011.10459.x)
- Ingram, J. R. et al. 2011. An unusual complication of jaundice [Abstract]. British Journal of Dermatology 164 (5), pp.1168-1168. (10.1111/j.1365-2133.2011.10357.x)
- Ingram, J. R. et al. 2011. Absence of pathogenic gamma-secretase mutations in familial and sporadic acne inversa in a European population [Abstract]. Journal of Investigative Dermatology 131 (Supp 2), pp.S68-S68. (10.1038/jid.2011.214)
2010
- Ingram, J. R. , Grindlay, D. J. C. and Williams, H. C. 2010. Management of "acne vulgaris": an evidence-based update. Clinical and Experimental Dermatology 35 (4), pp.351-354. (10.1111/j.1365-2230.2009.03683.x)
- Ingram, J. R. , Grindlay, D. J. C. and Williams, H. C. 2010. Problems in the reporting of acne clinical trials: a spot check from the 2009 Annual Evidence Update on Acne Vulgaris. Trials 11 77. (10.1186%2F1745-6215-11-77)
- Paulden, M. et al., 2010. Alitretinoin for the treatment of severe chronic hand eczema. Health Technology Assessment 14 , pp.39-46. (10.3310/hta14Suppl1/06)
- Rodgers, M. et al., 2010. Alitretinoin for severe chronic hand eczema: a NICE single technology appraisal. Pharmacoeconomics 28 (5), pp.351-362. (10.2165/11532160-000000000-00000.)
2009
- Batchelor, J. M. , Ingram, J. R. and Williams, H. 2009. Adalimumab vs Methotrexate for the treatment of chronic plaque psoriasis. Archives of Dermatology 145 (6), pp.704-706. (10.1001/archdermatol.2009.104)
- Ingram, J. R. 2009. Nicotine: does it have a role in the treatment of skin disease?. Postgraduate Medical Journal 85 (1002), pp.196-201. (10.1136/pgmj.2008.073577.)
- Ingram, J. R. , Batchelor, J. M. and Williams, H. C. 2009. Alitretinoin as a potential advance in the management of severe chronic hand eczema. Archives of Dermatology 145 (3), pp.314-315. (10.1001/archdermatol.2008.608.)
- Ingram, J. R. , Griffiths, A. P. and Roberts, D. L. 2009. All patients with sebaceous gland neoplasms should be screened for Muir-Torre syndrome. Clinical and Experimental Dermatology 34 (2), pp.264-266. (10.1111/j.1365-2230.2008.02830.x)
- Ingram, J. R. , Martin, J. A. and Finlay, A. Y. 2009. Impact of topical calcineurin inhibitors on quality of life in patients with atopic dermatitis. American Journal of Clinical Dermatology 10 (4), pp.229-237. (10.2165/00128071-200910040-00003.)
2008
- Ingram, J. R. , Hughes, M. and Stone, N. M. 2008. Occupational allergic contact dermatitis to polyfunctional aziridine crosslinker in a 'tufter'. Contact Dermatitis 58 (3), pp.172-U7. (10.1111/j.1600-0536.2007.01216.x)
- Ingram, J. R. et al. 2008. Nicotine enemas for active Crohn's colitis: an open pilot study. Gastroenterology Research and Practice 2008 237185.
2005
- Ingram, J. R. et al. 2005. Plasma fibrinogen in ulcerative colitis: The effect of disease activity and nicotine therapy in a randomised controlled trial. Digestive and Liver Disease 37 (11), pp.832-837. (10.1016/j.dld.2005.05.010)
- Ingram, J. R. et al. 2005. Preliminary observations of oral nicotine therapy for inflammatory bowel disease: An open-label phase I-II study of tolerance. Inflammatory Bowel Diseases 11 (12), pp.1092-1096.
- Ingram, J. R. et al. 2005. A randomized trial of nicotine enemas for active ulcerative colitis. Clinical Gastroenterology and Hepatology 3 (11), pp.1107-1114. (10.1016/S1542-3565(05)00849-9)
- Thomas, G. A. O. , Rhodes, J. and Ingram, J. R. 2005. Mechanisms of disease: nicotine - a review of its actions in the context of gastrointestinal disease. Nature Clinical Practice Gastroenterology & Hepatology 2 (11), pp.536-544. (10.1038/ncpgasthep0316)
Articles
- Ahmed, A. et al., 2024. Clinical relevance and uptake of core outcome sets in dermatology [Research letter]. Archives of Dermatological Research 316 (2) 78. (10.1007/s00403-023-02814-z)
- Ahmed, A. et al., 2024. Methodological innovations and stakeholder involvement in core outcome sets for skin diseases: a survey of the C3 working groups. Archives of Dermatological Research 316 (4) 109. (10.1007/s00403-023-02812-1)
- Ahmed, S. et al., 2020. Consent for publication: why it matters now more than ever. British Journal of Dermatology 183 (3), pp.409-410. (10.1111/bjd.19320)
- Ahmed, S. et al., 2023. Visualising complexity: embracing graphical abstracts in the BJD [Editorial]. British Journal of Dermatology 189 (2), pp.149-150. (10.1093/bjd/ljad181)
- Alexander, H. et al., 2024. A prospective observational cohort study comparing the treatment effectiveness and safety of ciclosporin, dupilumab and methotrexate in adult and paediatric patients with atopic dermatitis: results from the UK-Irish A-STAR register. British Journal of Dermatology 191 (6), pp.988-999. (10.1093/bjd/ljae287)
- Ali, F. et al. 2011. X-linked dominant protoporphyria due to a novel mutation in ALAS2: a case report [Abstract]. British Journal of Dermatology 164 (5), pp.1167-1167. (10.1111/j.1365-2133.2011.10357.x)
- Altayeb, A. et al., 2020. Two cases of skin manifestations prior to the onset of COVID-19 respiratory symptoms. International Journal of Dermatology 59 (12), pp.1541-1542. (10.1111/ijd.15247)
- Atwan, A. et al., 2016. Oral fumaric acid esters for psoriasis: abridged Cochrane systematic review including GRADE assessments. British Journal of Dermatology 175 (5), pp.873-881. (10.1111/bjd.14676)
- Atwan, A. et al., 2015. Oral fumaric acid esters for psoriasis. Cochrane Database of Systematic Reviews (8) CD010497. (10.1002/14651858.CD010497.pub2)
- Atwan, A. et al., 2017. Dermatology life quality index (DLQI) as a psoriasis referral triage tool. British Journal of Dermatology 177 (4), pp.e136-e137. (10.1111/bjd.15446)
- Batchelor, J. M. , Ingram, J. R. and Williams, H. 2009. Adalimumab vs Methotrexate for the treatment of chronic plaque psoriasis. Archives of Dermatology 145 (6), pp.704-706. (10.1001/archdermatol.2009.104)
- Bates, J. et al., 2022. Treatment of Hidradenitis Suppurativa Evaluation Study (THESEUS): protocol for a prospective cohort study. BMJ Open 12 (4) e060815. (10.1136/bmjopen-2022-060815)
- Bechara, F. G. et al., 2025. Towards a paradigm shift in delivering hidradenitis suppurativa care: a narrative review. Dermatology and Therapy 15 , pp.2317-2333. (10.1007/s13555-025-01462-7)
- Bosma, A. L. et al., 2023. Comparison of real-world treatment outcomes of systemic immunomodulating therapy in atopic dermatitis patients with dark and light skin types. JAAD International 10 , pp.14-24. (10.1016/j.jdin.2022.09.006)
- Bouazzi, D. et al., 2024. The Global Hidradenitis Suppurativa Atlas (GHiSA) methodology: Combining global proportions in a pooled analysis. Dermatology 240 (3), pp.369-375. (10.1159/000536389)
- Bouazzi, D. et al., 2025. Prevalence of hidradenitis suppurativa. JAMA Dermatology 161 (10), pp.1022-1028. (10.1001/jamadermatol.2025.2373)
- Burgin, S. et al., 2021. The essential role of dermatology publications in enhancing professional diversity, equity and inclusion. British Journal of Dermatology 185 (3), pp.473-474. (10.1111/bjd.20473)
- Burgin, S. et al., 2021. The essential role of dermatology publications in enhancing professional diversity, equity, and inclusion. Journal of Cosmetic Dermatology 20 (10), pp.3060-3061. (10.1111/jocd.14435)
- Burr, M. L. et al. 2013. The natural history of eczema from birth to adult life: a cohort study. British Journal of Dermatology 168 (6), pp.1339-1342. (10.1111/bjd.12216)
- Callander, J. et al., 2017. How to write a Critically Appraised Topic: evidence to underpin routine clinical practice. British Journal of Dermatology 177 (4), pp.1007-1013. (10.1111/bjd.15873)
- Callander, J. et al. 2018. Treatment of clinically amyopathic dermatomyositis in adults: a systematic review. British Journal of Dermatology 179 (6), pp.1248-1255. (10.1111/bjd.14726)
- Chalmers, J. R. et al., 2015. A randomized controlled trial to compare the safety and effectiveness of doxycycline (200 mg daily) with oral prednisolone (0·5 mg kg-1 daily) for initial treatment of bullous pemphigoid: a protocol for the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) trial. British Journal of Dermatology 173 (1), pp.227-234. (10.1111/bjd.13729)
- Chin, M. F. et al., 2014. Patient-reported outcome measure of pain experienced during administration of local anaesthesia in cutaneous surgery: a tool for appraisal [Abstract]. British Journal of Dermatology 171 , pp.80-80.
- Collier, F. et al., 2021. Primary care management of hidradenitis suppurativa: a cross-sectional survey of UK GPs. British Journal of General Practice Open 0051. (10.3399/BJGPO.2021.0051)
- Craig, F. F. et al., 2012. UK Dermatology Clinical Trials Network's STOP GAP trial (a multicentre trial of prednisolone versus ciclosporin for pyoderma gangrenosum): protocol for a randomised controlled trial. Trials 13 (1), pp.51. (10.1186/1745-6215-13-51)
- Cro, S. et al., 2022. Anakinra for palmoplantar pustulosis: results from a randomized, double-blind, multicentre, two staged, adaptive placebo controlled trial (APRICOT). British Journal of Dermatology 186 (2), pp.245-256. (10.1111/bjd.20653)
- Daxhelet, M. et al., 2016. Establishment of a European Registry for hidradenitis suppurativa/acne inversa by using an open source software. Journal of the European Academy of Dermatology and Venereology 30 (8), pp.1424-1426. (10.1111/jdv.13267)
- Drucker, A. M. and Ingram, J. R. 2021. Widening the tightrope: new abstract guidelines for BJD authors. British Journal of Dermatology 185 (4), pp.687-688. (10.1111/bjd.20498)
- Enk, A. , Ingram, J. R. and Piguet, V. 2012. Future leaders: mentor investment in young investigators. Journal of Investigative Dermatology 132 (8), pp.1943-1944. (10.1038/jid.2012.55)
- Freeman, E. E. et al., 2020. International collaboration and rapid harmonization across dermatologic COVID-19 registries. Journal of The American Academy of Dermatology (10.1016/j.jaad.2020.06.050)
- Frew, J. W. et al., 2021. Global harmonization of morphological definitions in hidradenitis suppurativa for a proposed glossary. JAMA Dermatology 157 (4), pp.449-455. (10.1001/jamadermatol.2020.5467)
- Frew, J. et al., 2019. Defining lesional, perilesional and unaffected skin in hidradenitis suppurativa: proposed recommendations for clinical trials and translational research studies. British Journal of Dermatology 181 (6)(10.1111/bjd.18309)
- Garcia-Doval, I. et al., 2018. Optimizing case reports and case series: guidance on how to improve quality. British Journal of Dermatology 178 (6), pp.1257-1262. (10.1111/bjd.16467)
- Garcia-Doval, I. et al., 2017. Systematic reviews: let's keep them trustworthy. British Journal of Dermatology 177 (4), pp.888-889. (10.1111/bjd.15826)
- Garg, A. et al., 2022. Shifting focus from “what we do” to the “impact of what we do”: Application of outcome measures to routine clinical care in dermatology. Journal of The American Academy of Dermatology 87 , pp.83-84. (10.1016/j.jaad.2022.04.042)
- Garg, A. et al., 2024. Addressing high placebo response rates in randomized clinical trials for hidradenitis suppurativa. British Journal of Dermatology 190 (3), pp.427-429. (10.1093/bjd/ljad375)
- Garg, A. et al., 2020. Evaluating patients' unmet needs in hidradenitis suppurativa: results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project. Journal of The American Academy of Dermatology 82 (2)(10.1016/j.jaad.2019.06.1301)
- Garg, A. et al., 2023. Factors associated with disease-specific life impact in patients with hidradenitis suppurativa: results from the Global VOICE project. British Journal of Dermatology 188 (6), pp.808-810. (10.1093/bjd/ljad069)
- Garg, A. et al., 2025. Standardization of lesion classification and assessment by investigators in clinical trials for hidradenitis suppurativa. JAMA Dermatology (10.1001/jamadermatol.2025.4652)
- Garg, A. et al., 2023. Validation of the Hidradenitis Suppurativa Investigator Global Assessment. JAMA Dermatology 159 (6), pp.606-612. (10.1001/jamadermatol.2023.0797)
- Garg, A. et al., 2022. Development and initial validation of the HS‐IGA: a novel hidradenitis suppurativa‐specific investigator global assessment for use in interventional trials. British Journal of Dermatology 187 (2), pp.203-210. (10.1111/bjd.21236)
- George, S. and Ingram, J. 2018. BJD support for dermatology journal clubs: nurturing Sir William Osler's legacy. British Journal of Dermatology 178 (2), pp.313-314. (10.1111/bjd.16164)
- George, S. and Ingram, J. R. 2015. Introducing cover image as a new category of publication in the BJD. British Journal of Dermatology 173 (2), pp.315-315. (10.1111/bjd.13964)
- Gribaleva, E. et al., 2025. The UK-Irish Atopic eczema Systemic TherApy Register (A*STAR): Baseline characteristics of the cohort. British Journal of Dermatology 192 (5), pp.927-930. (10.1093/bjd/ljaf039)
- Guckian, J. et al., 2021. Dermatology is finally talking about race. British Journal of Dermatology 185 (5), pp.875-876. (10.1111/bjd.20599)
- Hasan, S. B. et al. 2021. British Association of Dermatologists (BAD) national clinical audit on the management of Hidradenitis Suppurativa (HS) in the UK. Clinical and Experimental Dermatology 46 (6), pp.1023-1027. (10.1111/ced.14598)
- Hasan, S. et al. 2022. Pain measurement in painful skin conditions and rheumatoid arthritis randomized controlled trials: A scoping review to inform pain measurement in hidradenitis suppurativa. British Journal of Dermatology 187 (6), pp.846-854. (10.1111/bjd.21821)
- Hasan, S. B. et al. 2024. Feasibility of daily pain measurement using text messages in Hidradenitis Suppurativa clinical trials; Data from THESEUS study. British Journal of Dermatology 190 (5), pp.775-777. ljae057. (10.1093/bjd/ljae057)
- Hasan, S. , Ali, F. and Ingram, J. 2020. Cholinergic pruritus responding to Omalizumab. Clinical and Experimental Dermatology 45 (2), pp.264-266. (10.1111/ced.14052)
- Hasan, S. and Ingram, J. 2020. What has changed in the UK management of hidradenitis suppurativa from 2014 to 2019?. British Journal of Dermatology 183 (5), pp.973-975. (10.1111/bjd.19302)
- Hernandez-Cordero, A. et al., 2024. A genome-wide meta-analysis of palmoplantar pustulosis implicates TH2 responses and cigarette smoking in disease pathogenesis. Journal of Allergy and Clinical Immunology 154 (3), pp.657-665. (10.1016/j.jaci.2024.05.015)
- Ho, B. et al., 2019. A survey of the treatment and management of patients with severe chronic spontaneous urticaria. Clinical and Experimental Dermatology 44 (3), pp.353-355. (10.1111/ced.13778)
- Hodges, N. , Anstey, A. and Ingram, J. R. 2012. Fumaric acid esters for psoriasis: patient perceptions of an unlicensed medication [Abstract]. Journal of the American Academy of Dermatology 66 (4), pp.AB193-AB193. (10.1016/j.jaad.2011.11.809)
- Holgersen, N. et al., 2025. Impact of psychiatric disease and treatment on biologic drug survival in patients with hidradenitis suppurativa. Journal of The American Academy of Dermatology (10.1016/j.jaad.2025.09.037)
- Howells, L. et al., 2021. Thematic synthesis of the experiences of people with Hidradenitis Suppurativa: a systematic review. British Journal of Dermatology 185 (5), pp.921-934. (10.1111/bjd.20523)
- Howells, L. et al., 2025. A qualitative interview study exploring patient views and experiences of treatment for hidradenitis suppurativa in the UK. British Journal of Dermatology 193 (1), pp.85-92. ljaf046. (10.1093/bjd/ljaf046)
- Howes, R. et al., 2022. The surgical management of hidradenitis suppurativa in the United Kingdom: a national survey of care pathways informing the THESEUS study. Journal of Plastic, Reconstructive and Aesthetic Surgery 75 (1), pp.240-247. (10.1016/j.bjps.2021.08.038)
- Hundal, S. et al., 2025. Cost-utility analysis of clinic-based deroofing versus local excision for hidradenitis suppurativa. Journal of The American Academy of Dermatology 92 (4), pp.773-780. (10.1016/j.jaad.2024.11.057)
- Ingram, J. R. et al. 2020. The prevalence of hidradenitis suppurativa is shown by the Secure Anonymised Information Linkage (SAIL) Databank to be one per cent of the population of Wales. British Journal of Dermatology 183 (5), pp.950-952. (10.1111/bjd.19210)
- Ingram, J. R. et al. 2025. Hidradenitis suppurativa with and without draining tunnels: A real-world study characterizing differences in treatment and disease burden. Journal of the European Academy of Dermatology and Venereology (10.1111/jdv.20550)
- Ingram, J. 2014. Hidradenitis suppurativa outcome measures and treatment goals. British Journal of Dermatology 171 (6), pp.1293-1294. (10.1111/bjd.13396)
- Ingram, J. 2014. The quest for excellence (part 1): becoming a reviewer for the British Journal of Dermatology. British Journal of Dermatology 171 (5), pp.921-922. (10.1111/bjd.13404)
- Ingram, J. 2014. The quest for excellence (part 2): reviewing a clinical trial for the British Journal of Dermatology. British Journal of Dermatology 171 (6), pp.1277-1278. (10.1111/bjd.13445)
- Ingram, J. et al. 2018. Levels of wound calprotectin and other inflammatory biomarkers aid in deciding which patients with a diabetic foot ulcer need antibiotic therapy (INDUCE study). Diabetic Medicine 35 (2), pp.255-261. (10.1111/dme.13431)
- Ingram, J. R. 2023. A watershed moment for the BJD: Authors retain their article copyright. British Journal of Dermatology 188 (1), pp.1-2. (10.1093/bjd/ljac006)
- Ingram, J. R. 2018. Atopic eczema and cardiovascular disease. BMJ 361 k2064. (10.1136/bmj.k2064)
- Ingram, J. R. 2016. Hidradenitis suppurativa: an update. Clinical Medicine 16 (1), pp.70-73. (10.7861/clinmedicine.16-1-70)
- Ingram, J. R. 2025. Hidradenitis suppurativa: BJD state-of-the-art review series. British Journal of Dermatology 192 (Supp_1), pp.i1-i2. (10.1093/bjd/ljae455)
- Ingram, J. R. 2013. Interpreting outcome measures and defining treatment success. British Journal of Dermatology 169 (6), pp.1177-1178. (10.1111/bjd.12709)
- Ingram, J. R. 2017. Interventions for hidradenitis suppurativa. JAMA Dermatology 153 (5), pp.458-459. (10.1001/jamadermatol.2017.0432)
- Ingram, J. R. 2025. Mechanistic insights into ruxolitinib cream for mild hidradenitis suppurativa. British Journal of Dermatology 192 (5), pp.789-790. ljaf019. (10.1093/bjd/ljaf019)
- Ingram, J. R. 2009. Nicotine: does it have a role in the treatment of skin disease?. Postgraduate Medical Journal 85 (1002), pp.196-201. (10.1136/pgmj.2008.073577.)
- Ingram, J. R. 2011. The aetiology of acne inversa: an evolving story. British Journal of Dermatology 165 (2), pp.231-232. (10.1111/j.1365-2133.2011.10459.x)
- Ingram, J. R. 2020. The epidemiology of hidradenitis suppurativa. British Journal of Dermatology 183 (6), pp.990-998. (10.1111/bjd.19435)
- Ingram, J. R. 2016. The genetics of Hidradenitis Suppurativa. Dermatologic Clinics 34 (1), pp.23-28. (10.1016/j.det.2015.07.002)
- Ingram, J. R. et al. 2014. The Hidradenitis Suppurativa Priority Setting Partnership. British Journal of Dermatology 171 (6), pp.1422-1427. (10.1111/bjd.13163)
- Ingram, J. R. , Anderson, E. J. and Pugsley, L. 2013. Difficulty giving feedback on underperformance undermines the educational value of multi-source feedback. Medical Teacher 35 (10), pp.838-846. (10.3109/0142159X.2013.804910)
- Ingram, J. R. and Anstey, A. 2017. The evolution of clinical guidelines for dermatologists: GRADE, AGREE and occasionally consensus by experts. British Journal of Dermatology 176 (1), pp.3-4. (10.1111/bjd.15178)
- Ingram, J. R. , Anstey, A. V. and Piguet, V. 2012. Combination treatment with a tumour necrosis factor antagonist and an oral retinoid: efficacy in severe acral psoriasis? [Letter]. British Journal Of Dermatology 167 (4), pp.949-951. (10.1111/j.1365-2133.2012.10983.x)
- Ingram, J. R. , Batchelor, J. M. and Williams, H. C. 2009. Alitretinoin as a potential advance in the management of severe chronic hand eczema. Archives of Dermatology 145 (3), pp.314-315. (10.1001/archdermatol.2008.608.)
- Ingram, J. R. et al. 2023. Treatment of hidradenitis suppurativa evaluation study: the THESEUS prospective cohort study. Health Technology Assessment 27 30. (10.3310/HWNM2189)
- Ingram, J. R. et al. 2024. Treatment of hidradenitis suppurativa evaluation study (THESEUS): a prospective cohort study. British Journal of Dermatology 190 (3), pp.382-391. (10.1093/bjd/ljad388)
- Ingram, J. R. et al. 2013. Segmental cherry angiomas associated with extragenital lichen sclerosus: a report of two cases. Clinical and Experimental Dermatology 38 (4), pp.386-389. (10.1111/j.1365-2230.2012.04479.x)
- Ingram, J. R. et al. 2024. Treatment satisfaction in patients with hidradenitis suppurativa: A real-world survey from the EU5 and US. Dermatology (10.1159/000542343)
- Ingram, J. R. and Burton, T. 2017. NICE approval of adalimumab for moderate-to-severe hidradenitis suppurativa: the end of the beginning for hidradenitis suppurativa therapeutics?. British Journal of Dermatology 176 (2), pp.281-282. (10.1111/bjd.15255)
- Ingram, J. R. et al. 2023. Electronic patient-reported outcomes in hidradenitis suppurativa: content validity and usability of the electronic hidradenitis suppurativa symptom daily diary, hidradenitis suppurativa symptom questionnaire and hidradenitis suppurativa quality of life questionnaire. Dermatology (10.1159/000534463)
- Ingram, J. R. et al. 2011. An unusual complication of jaundice [Abstract]. British Journal of Dermatology 164 (5), pp.1168-1168. (10.1111/j.1365-2133.2011.10357.x)
- Ingram, J. R. et al. 2014. A Cochrane Systematic Review of interventions for Hidradenitis Suppurativa. Journal of Investigative Dermatology 134 , pp.S40-S40.
- Ingram, J. R. et al. 2025. Bimekizumab pain outcomes in patients with hidradenitis suppurativa: pooled 48-week results from BE HEARD I&II phase 3 randomized clinical trials. Pain and Therapy 14 , pp.1861-1878. (10.1007/s40122-025-00779-7)
- Ingram, J. R. et al. 2012. A bum deal from wooden toilet seats: reemergence of allergic contact dermatitis. Dermatitis 23 (5), pp.244-245.
- Ingram, J. R. et al. 2024. Comprehensive codified algorithms to identify the underestimated burden of hidradenitis suppurativa in the United States. Dermatology and Therapy 14 , pp.2859–2876. (10.1007/s13555-024-01259-0)
- Ingram, J. R. , Griffiths, A. P. and Roberts, D. L. 2009. All patients with sebaceous gland neoplasms should be screened for Muir-Torre syndrome. Clinical and Experimental Dermatology 34 (2), pp.264-266. (10.1111/j.1365-2230.2008.02830.x)
- Ingram, J. R. , Grindlay, D. J. C. and Williams, H. C. 2010. Management of "acne vulgaris": an evidence-based update. Clinical and Experimental Dermatology 35 (4), pp.351-354. (10.1111/j.1365-2230.2009.03683.x)
- Ingram, J. R. , Grindlay, D. J. C. and Williams, H. C. 2010. Problems in the reporting of acne clinical trials: a spot check from the 2009 Annual Evidence Update on Acne Vulgaris. Trials 11 77. (10.1186%2F1745-6215-11-77)
- Ingram, J. R. , Hadjieconomou, S. and Piguet, V. 2016. Development of core outcome sets in hidradenitis suppurativa:a systematic review of outcome measure instruments to inform the process. British Journal of Dermatology 175 (2), pp.263-272. (10.1111/bjd.14475)
- Ingram, J. R. , Hughes, M. and Stone, N. M. 2008. Occupational allergic contact dermatitis to polyfunctional aziridine crosslinker in a 'tufter'. Contact Dermatitis 58 (3), pp.172-U7. (10.1111/j.1600-0536.2007.01216.x)
- Ingram, J. R. , Hughes, T. M. and Stone, N. M. 2014. Potential danger of hair dyes marketed as free from para-phenylenediamine. International Journal of Dermatology 53 (4), pp.e257-e258. (10.1111/ijd.12296)
- Ingram, J. R. et al. 2018. Population-based Clinical Practice Research Datalink study using algorithm modelling to identify the true burden of hidradenitis suppurativa. British Journal of Dermatology 178 (4), pp.917-924. (10.1111/bjd.16101)
- Ingram, J. R. et al. 2025. Implementation science to improve the diagnosis and management of hidradenitis suppurativa: HELyx study design overview. Dermatology and Therapy 15 (2), pp.463–472. (10.1007/s13555-025-01350-0)
- Ingram, J. R. et al. 2025. Hidradenitis suppurativa symptom daily diary (HSSDD) and questionnaire (HSSQ): psychometric validation and interpretation threshold derivation using phase 3 study data. Dermatology and Therapy 15 , pp.1093-1111. (10.1007/s13555-025-01346-w)
- Ingram, J. R. , Martin, J. A. and Finlay, A. Y. 2009. Impact of topical calcineurin inhibitors on quality of life in patients with atopic dermatitis. American Journal of Clinical Dermatology 10 (4), pp.229-237. (10.2165/00128071-200910040-00003.)
- Ingram, J. R. and McPhee, M. 2015. Management of hidradenitis suppurativa: a UK survey of current practice. British Journal of Dermatology 173 (4), pp.1070-1072. (10.1111/bjd.13866)
- Ingram, J. R. and Paul, C. 2015. Academic mentorship in dermatology. British Journal of Dermatology 173 (5), pp.1113-1114. (10.1111/bjd.14197)
- Ingram, J. R. and Piguet, V. 2013. Phenotypic heterogeneity in Hidradenitis Suppurativa (Acne Inversa): classification is an essential step toward personalized therapy. Journal of Investigative Dermatology 133 (6), pp.1453-1456. (10.1038/jid.2012.476)
- Ingram, J. R. et al. 2005. Plasma fibrinogen in ulcerative colitis: The effect of disease activity and nicotine therapy in a randomised controlled trial. Digestive and Liver Disease 37 (11), pp.832-837. (10.1016/j.dld.2005.05.010)
- Ingram, J. R. et al. 2008. Nicotine enemas for active Crohn's colitis: an open pilot study. Gastroenterology Research and Practice 2008 237185.
- Ingram, J. R. et al. 2005. Preliminary observations of oral nicotine therapy for inflammatory bowel disease: An open-label phase I-II study of tolerance. Inflammatory Bowel Diseases 11 (12), pp.1092-1096.
- Ingram, J. R. et al. 2025. Assessing long-term pain reduction with secukinumab in moderate to severe hidradenitis suppurativa: a post hoc analysis of the SUNSHINE and SUNRISE Phase 3 trials. Dermatology and Therapy (10.1007/s13555-025-01426-x)
- Ingram, J. R. et al. 2005. A randomized trial of nicotine enemas for active ulcerative colitis. Clinical Gastroenterology and Hepatology 3 (11), pp.1107-1114. (10.1016/S1542-3565(05)00849-9)
- Ingram, J. R. et al. 2016. Interventions for hidradenitis suppurativa: a Cochrane systematic review incorporating GRADE assessment of evidence quality. British Journal of Dermatology 174 (5), pp.970-978. (10.1111/bjd.14418)
- Ingram, J. R. et al. 2015. Interventions for hidradenitis suppurativa. Cochrane Database of Systematic Reviews (10) CD010081. (10.1002/14651858.CD010081.pub2)
- Ingram, J. R. et al. 2013. Absence of pathogenic γ-secretase mutations in a South Wales cohort of familial and sporadic hidradenitis suppurativa (acne inversa). British Journal Of Dermatology 168 (4), pp.874-876. (10.1111/bjd.12048)
- Ingram, J. R. et al. 2011. Absence of pathogenic gamma-secretase mutations in familial and sporadic acne inversa in a European population [Abstract]. Journal of Investigative Dermatology 131 (Supp 2), pp.S68-S68. (10.1038/jid.2011.214)
- Ingram, J. R. et al. 2025. The Hidradenitis suppurativa symptom and impact diary: development and psychometric evaluation of a novel set of patient reported outcomes for hidradenitis suppurativa. British Journal of Dermatology 193 (6), pp.1155-1164. (10.1093/bjd/ljaf307)
- Ingram, J. 2019. BJD: onwards and upwards. British Journal of Dermatology 181 (1), pp.1-2. (10.1111/bjd.18034)
- Ingram, J. and Ahluwalia, A. 2021. The pharmacology of itch. British Journal of Dermatology 184 (1), pp.e1-e2. (10.1111/bjd.18525)
- Ingram, J. et al. 2022. Unmet clinical needs and burden of disease in hidradenitis suppurativa: real-world experience from EU5 and US. Journal of the European Academy of Dermatology and Venereology 36 (9), pp.1597-1605. (10.1111/jdv.18163)
- Ingram, J. et al. 2019. British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018. British Journal of Dermatology 180 (5), pp.1009-1017. (10.1111/bjd.17537)
- James, J. F. et al., 2023. Demographic gaps and requirements for participation: A systematic review of clinical trial designs in Hidradenitis Suppurativa. Dermatology 239 , pp.45-51. (10.1159/000526069)
- Jedrzejczak, M. J. et al., 2021. Expert knowledge, attitudes, and practices in management of hidradenitis suppurativa pain. JAMA Dermatology 157 (4), pp.464-466. (10.1001/jamadermatol.2020.5857)
- Johns, J. R. et al. 2024. The Dermatology Life Quality Index as the primary outcome in randomized clinical trials: a systematic review. British Journal of Dermatology 191 (4), pp.497-507. (10.1093/bjd/ljae228)
- Jung, F. et al., 2020. Systematic review of efficacies and adverse effects of treatments for Pityriasis lichenoides. British Journal of Dermatology 183 (6), pp.1026-1032. (10.1111/bjd.18977)
- Kimball, A. B. et al., 2024. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials. The Lancet 403 (10443), pp.2504-2519. (10.1016/S0140-6736(24)00101-6)
- Kimball, A. B. et al., 2024. Burden of hidradenitis suppurativa: a systematic literature review of patient reported outcomes. Dermatology and Therapy 14 , pp.83–98. (10.1007/s13555-023-01085-w)
- Kirby, J. .. et al., 2021. Validation of patient global item for quality of life impact on Hidradenitis suppurativa. British Journal of Dermatology 184 (4), pp.681-687. (10.1111/bjd.19344)
- Kirby, J. S. et al., 2025. Psychometric validation and interpretation thresholds of the Hidradenitis Suppurativa Quality of Life (HiSQOL©) questionnaire using pooled data from the Phase 3 BE HEARD I & II trials of bimekizumab in hidradenitis suppurativa. British Journal of Dermatology 193 (1), pp.93-104. (10.1093/bjd/ljaf067)
- Kirby, J. et al., 2020. The Hidradenitis Suppurativa Quality of Life (HiSQOL) score: development and validation of a measure for clinical trials. British Journal of Dermatology 183 (2), pp.340-348. (10.1111/bjd.18692)
- Leighton, P. et al., 2023. Research priorities in the management of Hidradenitis Suppurativa [Research Letter]. British Journal of Dermatology 189 (3), pp.343-345. (10.1093/bjd/ljad152)
- Li, Y. H. et al., 2025. Comparing maximum and average numerical rating scale pain scores in hidradenitis suppurativa. Archives of Dermatological Research 317 (1) 496. (10.1007/s00403-025-03943-3)
- Maghfour, J. et al., 2022. From the Cochrane Library: interventions for hidradenitis suppurativa. JMIR Dermatology 5 (1) e29966. (10.2196/29966)
- Maronese, C. A. , Ingram, J. R. and Marzano, A. V. 2023. Has the time come to assess small-molecule/biologic drug combinations for the management of moderate-to-severe hidradenitis suppurativa?. British Journal of Dermatology 189 (4), pp.467–468. (10.1093/bjd/ljad224)
- Mastacouris, N. et al., 2023. Outcome measures for the evaluation of treatment response in hidradenitis suppurativa for clinical practice. JAMA Dermatology 159 (11), pp.1258-1266. (10.1001/jamadermatol.2023.3282)
- Matin, R. N. et al., 2013. The UK Dermatology Clinical Trials Network Trainee Group: developing evidence-based practice and research engagement among dermatology trainees. British Journal of Dermatology 169 , pp.35-35.
- McCluskey, D. et al., 2022. Single-cell analysis implicates Th17-to-Th2 cell plasticity in the pathogenesis of palmoplantar pustulosis. Journal of Allergy and Clinical Immunology 150 (4), pp.882-893. (10.1016/j.jaci.2022.04.027)
- Midgette, B. et al., 2023. Factors associated with treatment satisfaction in patients with hidradenitis suppurativa: results from the Global VOICE project. British Journal of Dermatology 187 (6), pp.927-935. (10.1111/bjd.21798)
- Millington, A. et al., 2020. Home-based narrowband UVB, topical corticosteroid or combination for children and adults with vitiligo: HI-Light Vitiligo three-arm RCT. Health Technology Assessment 24 (64), pp.1-183. (10.3310/hta24640)
- Mukkanna, K. S. , Stone, N. M. and Ingram, J. R. 2017. Para-phenylenediamine allergy: current perspectives on diagnosis and management. Journal of Asthma and Allergy 10 , pp.9-15. (10.2147/JAA.S90265)
- Nadir, U. et al., 2024. Protocol of a scoping review of outcome domains in dermatology. BMJ Open 14 (2) e079632. (10.1136/bmjopen-2023-079632)
- Naik, H. B. et al., 2022. Biologic therapy is not associated with increased COVID-19 severity in Hidradenitis Suppurativa: Initial findings from the Global Hidradenitis Suppurativa COVID-19 Registry. Journal of The American Academy of Dermatology 86 (1), pp.249-252. (10.1016/j.jaad.2021.09.016)
- Naik, H. B. et al., 2020. Global hidradenitis suppurativa COVID-19 registry: a registry to inform data-driven management practices. British Journal of Dermatology 183 (4), pp.780-781. (10.1111/bjd.19345)
- Nankervis, H. et al., 2015. Validation of the global resource of eczema trials (GREAT database). BMC Dermatology 15 (4)(10.1186/s12895-015-0024-z)
- Navarrete-Dechent, C. et al., 2024. The road to publication: Advice from journal editors. Journal of The American Academy of Dermatology 90 , pp.707-710. (10.1016/j.jaad.2023.11.038)
- Nikolakis, G. et al., 2025. Towards the development of upgrade criteria for the treatment of hidradenitis suppurativa with biologics. Journal of the European Academy of Dermatology and Venereology (10.1111/jdv.70118)
- Ormerod, A. D. et al., 2015. Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial. BMJ 350 h2958. (10.1136/bmj.h2958)
- Oyesiku, L. et al., 2024. Inclusive and equitable language for skin colour in the British Journal of Dermatology: acknowledging our past and laying the foundations to move forward. British Journal of Dermatology 190 (5), pp.605–607. (10.1093/bjd/ljae064)
- Paulden, M. et al., 2010. Alitretinoin for the treatment of severe chronic hand eczema. Health Technology Assessment 14 , pp.39-46. (10.3310/hta14Suppl1/06)
- Pickles, T. and Ingram, J. R. 2025. Minimal important difference of pain numeric rating scale in patients with Hidradenitis suppurativa: results from THESEUS. British Journal of Dermatology 192 (4), pp.761-763. ljae486. (10.1093/bjd/ljae486)
- Ponnambath, N. et al., 2013. Practical experience of biological treatment of very severe psoriasis: a retrospective case-cohort study of patients with a baseline Psoriasis Area and Severity Index score greater than 20 [Abstract]. British Journal of Dermatology 169 (s1), pp.41-41. (10.1111/bjd.12306)
- Prinsen, C. A. et al., 2019. Navigating the landscape of core outcome set development in dermatology. Journal of the American Academy of Dermatology 81 (1), pp.297-305. (10.1016/j.jaad.2019.03.009)
- Ring, H. C. et al., 2024. Long-term drug survival of adalimumab, infliximab, secukinumab and ustekinumab in hidradenitis suppurativa: A Danish nationwide cohort study. British Journal of Dermatology 190 (5), pp.769-771. ljae042. (10.1093/bjd/ljae042)
- Ring, H. C. et al., 2022. The road to biologics in patients with hidradenitis suppurativa - a nationwide drug utilization study. British Journal of Dermatology 187 (4), pp.523-530. (10.1111/bjd.21673)
- Rodgers, M. et al., 2010. Alitretinoin for severe chronic hand eczema: a NICE single technology appraisal. Pharmacoeconomics 28 (5), pp.351-362. (10.2165/11532160-000000000-00000.)
- Sach, T. et al., 2021. An economic evaluation of the randomised controlled trial of topical corticosteroid and home‐based narrowband UVB for active and limited vitiligo (The HI‐Light Trial). British Journal of Dermatology 184 (5), pp.840-848. (10.1111/bjd.19554)
- Sampath, A. J. et al., 2025. Standardized protocols for clinical and histopathological characterization of hidradenitis suppurativa tissue specimens. Journal of Investigative Dermatology 145 (1), pp.50-55. (10.1016/j.jid.2024.02.041)
- Sayed, C. J. et al., 2025. Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension. Journal of The American Academy of Dermatology (10.1016/j.jaad.2025.11.031)
- Sbidian, E. et al., 2017. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database of Systematic Reviews (12) CD011535. (10.1002/14651858.CD011535.pub2)
- Scrivens, L. , Jacquet, L. and Ingram, J. 2019. BJD Medical Student Editors: reaching out to undergraduates in a rapidly evolving world of digital dermatology publishing. British Journal of Dermatology 180 (2), pp.251-252. (10.1111/bjd.17397)
- Shah, R. et al. 2024. Measurement of the major ignored burden of multiple myeloma, pernicious anaemia and of other haematological conditions on partners and family members: A cross‐sectional study. European Journal of Haematology 113 (1), pp.117-126. (10.1111/ejh.14206)
- Shah, R. et al. 2024. Responsiveness and minimal important change of the Family Reported Outcome Measure (FROM-16). Journal of Patient-Reported Outcomes 8 (1) 38. (10.1186/s41687-024-00703-1)
- Shah, R. et al. 2024. Mapping of family reported outcome measure (FROM-16) scores to EQ-5D: algorithm to calculate utility values. Quality of Life Research 33 , pp.1107-1119. (10.1007/s11136-023-03590-z)
- Shah, R. et al. 2024. Dementia and its profound Impact on family members and partners. Alzheimer Disease & Associated Disorders 38 (4), pp.338-342. (10.1097/WAD.0000000000000647)
- Shah, R. et al. 2021. Measuring the impact of COVID-19 on the quality of life of the survivors, partners and family members: a cross-sectional international online survey. BMJ Open 11 (5) e047680. (10.1136/bmjopen-2020-047680)
- Shah, R. et al. 2025. Comparison of the impact of type 1 and type 2 diabetes on quality of life of families of patients: A UK cross‐sectional study. Diabetes, Obesity and Metabolism 27 (2), pp.652-662. (10.1111/dom.16058)
- Shah, R. et al. 2023. Meaning of Family Reported Outcome Measure (FROM-16) severity score bands: a cross-sectional online study in the UK. BMJ Open 13 (3) e066168. (10.1136/bmjopen-2022-066168)
- Shah, R. et al. 2025. Multiple sclerosis greatly impacts family members/partners: Evidence using the Family Reported Outcome Measure (FROM-16). Multiple Sclerosis Journal - Experimental, Translational and Clinical 11 (2) 20552173251338762. (10.1177/20552173251338762)
- Shi, V. Y. et al., 2025. Bimekizumab impact on patient-reported outcomes in patients with moderate to severe hidradenitis suppurativa: pooled 48-week results from BE HEARD I&II. Dermatology and Therapy 15 , pp.2553-2570. (10.1007/s13555-025-01465-4)
- Soriano, L. F. et al., 2020. Effectiveness of a stop smoking service in reducing cigarette smoking in patients referred from an NHS dermatology centre. British Journal of Dermatology 183 (6), pp.1119-1121. (10.1111/bjd.19378)
- Tang, H. K. C. et al., 2017. Delayed and localized pemphigus vulgaris after breast cancer radiotherapy. The Breast Journal 23 (6), pp.747-749. (10.1111/tbj.12910)
- Tappenden, P. et al., 2017. Adalimumab for treating moderate-to-severe hidradenitis suppurativa: an evidence review group perspective of a NICE single technology appraisal. PharmacoEconomics 35 (8), pp.805-815. (10.1007/s40273-017-0488-2)
- Tatovic, D. et al. 2022. Safety of the use of gold nanoparticles conjugated with proinsulin peptide and administered by hollow microneedles as an immunotherapy in Type 1 diabetes. Immunotherapy Advances 2 (1) ltac002. (10.1093/immadv/ltac002)
- Thomas, G. A. O. , Rhodes, J. and Ingram, J. R. 2005. Mechanisms of disease: nicotine - a review of its actions in the context of gastrointestinal disease. Nature Clinical Practice Gastroenterology & Hepatology 2 (11), pp.536-544. (10.1038/ncpgasthep0316)
- Thomas, K. S. et al., 2016. Clinical outcomes and response of patients applying topical therapy for pyoderma gangrenosum: a prospective cohort study. Journal of the American Academy of Dermatology 75 (5), pp.940-949. (10.1016/j.jaad.2016.06.016)
- Thomas, K. et al., 2021. Randomised controlled trial of topical corticosteroid and home-based narrowband UVB for active and limited vitiligo - results of the HI-Light Vitiligo trial. British Journal of Dermatology 184 (5), pp.828-839. (10.1111/bjd.19592)
- Thorlacius, L. et al., 2018. Towards global consensus on core outcomes for hidradenitis suppurativa research: an update from the HISTORIC consensus meetings I and II. British Journal of Dermatology 178 (3), pp.715-721. (10.1111/bjd.16093)
- Thorlacius, L. et al., 2018. A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process. British Journal of Dermatology 179 (3), pp.642-650. (10.1111/bjd.16672)
- Thorlacius, L. et al., 2017. Protocol for the development of a core domain set for hidradenitis suppurativa trial outcomes. BMJ Open 7 (2) e014733. (10.1136/bmjopen-2016-014733)
- Thorlacius, L. et al., 2025. The HIdradenitis suppurativa DrainagE (HIDE) Scale: development and content validation of patient reported outcome measure [Research Letter]. British Journal of Dermatology 193 (6), pp.1242-1244. (10.1093/bjd/ljaf317)
- van Dalen, S. C. M. et al., 2025. Neutrophil extracellular traps are widely distributed across lesional and perilesional hidradenitis suppurativa skin, and elevated serum NET markers associate with moderate to severe HS disease. International Journal of Dermatology 64 (7), pp.1234-1241. (10.1111/ijd.17706)
- van Huizen, A. M. et al., 2022. International eDelphi study to reach consensus on the methotrexate dosing regimen in patients with psoriasis. JAMA Dermatology 158 (5), pp.561-572. (10.1001/jamadermatol.2022.0434)
- van Straalen, K. R. et al., 2022. New treatments and new assessment instruments for hidradenitis suppurativa. Experimental Dermatology 31 (s1), pp.33-39. (10.1111/exd.14609)
- Vergnano, M. et al., 2020. Loss-of-function myeloperoxidase mutations are associated with increased neutrophil counts and pustular skin disease. American Journal of Human Genetics 107 (3), pp.539-543. (10.1016/j.ajhg.2020.06.020)
- Veysey, E. C. et al., 2021. Core outcome set implementation supported by the BJD. British Journal of Dermatology 184 (6), pp.987-989. (10.1111/bjd.20050)
- Vyas, J. et al. 2024. The Dermatology Life Quality Index (DLQI) used as the benchmark in validation of 101 quality of life instruments: A systematic review. Journal of the European Academy of Dermatology and Venereology (10.1111/jdv.20321)
- Vyas, J. et al. 2025. A systematic review of the use of the Dermatology Life Quality Index (DLQI) in routine clinical practice: evidence from 287 articles across 56 countries. Clinical and Experimental Dermatology 50 (12), pp.2456-2465. (10.1093/ced/llaf343)
- Vyas, J. et al. 2024. A systematic review of 207 studies describing validation aspects of the dermatology life quality index. Acta Dermato-Venereologica 104 adv41120. (10.2340/actadv.v104.41120)
- Vyas, J. et al. 2024. A systematic review of 457 randomised controlled trials using the Dermatology Life Quality Index: experience in 69 diseases and 43 countries. British Journal of Dermatology 190 (3), pp.315-339. (10.1093/bjd/ljad079)
- Wainman, H. E. et al., 2024. Global consensus process to establish a core data set for hidradenitis suppurativa registries. British Journal of Dermatology 190 (4), pp.510-518. (10.1093/bjd/ljad454)
- Wainman, H. E. et al., 2025. Management of hidradenitis suppurativa in UK primary care: cross-sectional survey. British Journal of General Practice Open (10.3399/BJGPO.2025.0060)
- Wainman, H. E. et al., 2025. Is there still a role for clindamycin and rifampicin in the treatment of hidradenitis suppurativa: A review of the literature. Clinical and Experimental Dermatology 50 (8), pp.1671-1676. (10.1093/ced/llaf160)
- Wainman, H. E. , Lane, P. C. and Ingram, J. R. 2023. Hidradenitis suppurativa diagnosis and management in primary care: not just recurrent boils. British Journal of General Practice 73 (726), pp.43-45. (10.3399/bjgp23X731733)
- Wall, D. et al., 2021. Learning from disease registries during a pandemic: Moving toward an international federation of patient registries. Clinics in Dermatology 39 (3), pp.467-478. (10.1016/j.clindermatol.2021.01.018)
- Warburton, K. L. et al., 2014. Management of morphoea: results of a national survey of UK clinicians. British Journal of Dermatology 171 (5), pp.1243-1245. (10.1111/bjd.13062)
- Wernham, A. et al., 2019. A five-year review of quality of reporting of research using clinician surveys in high-ranked dermatology journals. British Journal of Dermatology 181 (4), pp.845-847. (10.1111/bjd.17942)
- Wernham, A. , Ingram, J. R. and Matin, R. 2018. Clinician surveys: time to make better use of this valuable resource for dermatologists. British Journal of Dermatology 178 (6), pp.1466-1467. (10.1111/bjd.16444)
- Westerkam, L. L. et al., 2025. Establishment of standardized definitions and a core set of outcome characteristics following hidradenitis suppurativa surgery developed by an expert Delphi consensus. Journal of The American Academy of Dermatology 93 (6), pp.1499-1508. (10.1016/j.jaad.2025.08.041)
- Willems, D. et al., 2023. A discrete-choice experiment to elicit the treatment preferences of patients with hidradenitis suppurativa in the United States. Journal of Medical Economics (JME) 26 (1), pp.503-508. (10.1080/13696998.2023.2194804)
- Willems, D. et al., 2023. Patient preferences in the management of hidradenitis suppurativa: results of a multinational discrete choice experiment in Europe. The Patient - Patient-Centered Outcomes Research 16 (2), pp.153-164. (10.1007/s40271-022-00614-7)
- Williams, H. C. et al., 2017. Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial. Lancet 389 (10079), pp.1630-1638. (10.1016/S0140-6736(17)30560-3)
- Williams, J. C. et al., 2022. Biologic therapy is not associated with increased covid-19 severity in patients with hidradenitis suppurativa: updated findings from the global hidradenitis suppurativa covid-19 registry. Dermatology (10.1159/000527401)
- Williams, J. C. et al., 2023. Patient-reported influences on COVID-19 vaccine acceptance and hesitancy in people with hidradenitis suppurativa [Research Letter]. British Journal of Dermatology 189 (3), pp.351-353. (10.1093/bjd/ljad166)
- Yiu, Z. Z. N. et al., 2022. Checking for update…living systematic reviews and clinical practice guidelines in the BJD. British Journal of Dermatology 186 (5), pp.761-762. (10.1111/bjd.20896)
- Zouboulis, C. C. et al., 2025. European S2k guidelines for hidradenitis suppurativa/acne inversa part 2: Treatment. Journal of the European Academy of Dermatology and Venereology 39 (5), pp.899-941. (10.1111/jdv.20472)
- Zouboulis, C. C. et al., 2017. Development and validation of IHS4, a novel dynamic scoring system to assess hidradenitis suppurativa/acne inversa severity. British Journal of Dermatology 177 (5), pp.1401-1409. (10.1111/bjd.15748)
- Zouboulis, C. C. et al., 2020. What causes hidradenitis suppurativa ? - 15 years after. Experimental Dermatology 29 (12), pp.1154-1170. (10.1111/exd.14214)
- Zouboulis, C. C. et al., 2020. Endpoints of clinical trials for Hidradenitis Suppurativa: proceedings of a round-table session. Experimental Dermatology 29 (S1), pp.67-72. (10.1111/exd.14123)
- Zuuren, E. J. et al., 2020. Publication of national dermatology guidelines as a research letter in the BJD : can less ever be enough?. British Journal of Dermatology 182 (6), pp.1319-1320. (10.1111/bjd.18952)
Research
Hidradenitis Suppurativa
My research focuses on hidradenitis suppurativa (HS), a common, painful chronic inflammatory condition causing multiple boils in skin creases such as the arm pits and groin. Scarring including skin tunnels occurs in moderate to severe disease. HS typically affects young adults, affecting relationships, education, and careers, with a large impact on quality of life.
I led the guideline development group producing the first UK guidelines for HS in 2018 (https://pubmed.ncbi.nlm.nih.gov/30552762/). My five year HCRW fellowship used primary care data to identify undiagnosed patients living with HS, increasing HS prevalence estimates from 0.1% to 1.0%, demonstrating that HS is a common condition. I was chief investigator of the HTA-funded THESEUS study which introduced to the UK deroofing for skin tunnels, our information video being viewed more than 1.5 million times (https://www.youtube.com/watch?v=ftizgrBMzok).
The impact of my HS research is demonstrated by my impact case for the 2021 Research Excellence Framework (REF) process https://www.cardiff.ac.uk/medicine/research/impact/HS-skin-condition-research .
HiSTORIC and C3
I co-founded HiSTORIC, the Hidradenitis Suppurativa Core Outcomes Set International Collaboration, which defined the six core outcome domains, the 'what' to measure, in HS trials https://www.c3outcomes.org/historic. HiSTORIC is now identifying pre-existing validated instruments to measure each domain and is developing and validating new instruments where needed. I am co-copyright holder of the Hidradenitis Suppurativa Quality of Life (HiSQOL) instrument (https://research.med.psu.edu/hidradenitis-suppurativa/), as well as the Patient Global Assessment instrument to measure overall quality of life, and the HS Investigator Global Assessment (HS-IGA) tool.
HiSTORIC began supporting other dermatology core outcome set development groups, leading to creation of CHORD, Consortium for Harmonizing Outcomes Research in Dermatology. I co-founded C3, the CHORD COUSIN Collaboration, following a merger with the Cochrane Skin Core Outcomes Set Initiative (CS-COUSIN) and I am current C3 Treasurer. C3 now includes more than 20 dermatology core outcome set development groups https://www.c3outcomes.org/, providing resources and methodological support.
HS Biobank
I established a Cardiff HS database containing demographic and phenotype details linked to a biobank of tissue and blood samples held by the Cardiff University Biobank (CUB). Biobank samples are being investigated with several collaborators to improve our understanding of HS pathogenesis.
Research Students
In progress
- Dr Samar Hasan, PhD programme
- Dr Hannah Wainman, PhD programme
Awarded
- Dr Ausama Atwan, MD 2018
- Dr Faraz Ali, PhD 2021
- Dr Rubina Shah, PhD 2024
Teaching
Medical undergraduates
- Admissions interviewer
- Dermatology clinical tutor
- Academic mentor
- Finals ISCE examiner
Dermatology postgraduates
- Lecturer and examiner for Diploma & MSc in Clinical Dermatology
- Lecturer for MSc course and intercalated BSc medical undergraduate course in Medical Education
- Lead for Diploma in Practical Dermatology 2012–14. In this role I modularised the course, blueprinted assessments to level 7 learning outcomes and moved the Virtual Learning Environment to the Cardiff University Blackboard provider
Biography
Education & Qualifications
| FRCP(Derm) | Medicine | Royal College of Physicians | 2017 |
| FAcadMEd | Medical Education | Academy of Medical Educators | 2014 |
| MSc | Medical Education | Cardiff University | 2012 |
| Certificate of Completion of Training | Dermatology | General Medical Council | 2011 |
| DM (Oxon) | Medicine | Oxford University | 2008 |
| MA | Physiological Science | Oxford University | 2004 |
| MRCP (UK) | Medicine | Royal College of Physicians | 2002 |
| BM BCh | Medicine | Oxford University | 1999 |
| BA | Physiological Science | Oxford University | 1996 |
Career Overview
My present appointment is Professor of Dermatology, Cardiff University & Honorary Consultant Dermatologist, Cardiff & Vale University Health Board, first joining Cardiff University in 2011 as a clinical lecturer.
Previously I trained in dermatology on the South Wales Training Rotation and worked for 12 months in dermatology and general medicine in Australia. I performed my DM doctoral studies in Cardiff after completing my SHO medical rotation in South Wales and undertook all of my undergraduate medical training at Oxford University.
Honours and awards
- NHS Clinical Impact Award 2022-27
- Honorary Associate Professor, University of Toronto, 2020
- Awarded 5-year (£475,000) Research Fellowship, Health & Care Research Wales (HCRW), 2014-19
- Best Presentation Award, Aneurin Bevan Local Health Board R&D Conference, 2011
- Academy for Future Leaders in Dermatology Award, European Society for Dermatological Research, 2011
- Registrar Fellowship Award, UK Dermatology Clinical Trials Network (DCTN), 2007
- Hugh Wallace Essay & Publication Prize, Royal Society of Medicine, Dermatology Section, 2007
Professional memberships
Grant Advisory Committees
- British Skin Foundation Large Grant Advisory Committee member 2013-18
- HCRW Research for Patient and Public Benefit Grant Funding Board member 2016-17
Examination Boards
- Royal College of Physicians Dermatology Specialty Certificate Examination Board member 2013-18
UK Advisory Roles
- Clinical expert for four NICE single technology appraisals
- NICE Evidence Resources Reference Panel member - dual RCP & BAD representative
- Medical Adviser for Hidradenitis Suppurativa UK patient network
- Performed External Review of St John’s Hidradenitis Suppurativa clinical service at the request of Guy’s and St Thomas’ NHS Foundation Trust 2017
- Lead for British Association of Dermatologists HS Guideline Development Group 2015-19
- UK Department of Work & Pensions Adviser regarding HS disability
UK Dermatology Clinical Trials Network (UK DCTN)
- Steering Committee member
- Chair of Trial Generation and Prioritisation Panel (TGPP) 2014-18
All Wales Roles
- Health and Care Research Wales Dermatology Lead
Speaking engagements
- Keynote speaker at Symposium on HS Advances conference, Austin Texas 2024
- Session Chair and delivery of two oral presentations, European HS Foundation conference, Lyon 2024
- One of the few invited overseas speakers at American Academy of Dermatologists Annual meeting, San Diego 2024, New Orleans 2023, and Boston 2022
- Virtual speaker at the 2023 annual meetings of the two Chinese dermatology associations with a membership of more than 20,000 dermatologists
- Chair and speaker at the HS session of the 2023 World Congress of Dermatology, Singapore
- Plenary lecture, British Association of Dermatologists annual conference 2022, Glasgow
- Invited speaker at International Congress of Dermatology, Melbourne 2021